Scottsdale, AZ – May 3, 2022 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), clinical-stage developer of patented cell therapy technologies for the regeneration of skin and tissues, today announced the termination of its Strategic R&D Agreement with StemCell Systems and the closure of the RenovaCare R&D Innovation Center in Berlin, Germany.
Scottsdale, AZ – March 24, 2022 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), clinical-stage developer of patented cell therapy technologies for the regeneration of skin and tissues, today announced reductions in its management team to further streamline administrative expenses.
Scottsdale, AZ – March 09, 2022 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented cell therapy technologies for the regeneration of skin and tissues, today announced that following the review of its research and corporate activities, the Company is taking steps to streamline its clinical, research and development, and administrative operations in order to reduce costs.
Scottsdale, AZ – October 14, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented cell therapy technologies for the regeneration of skin and tissues, today announced the award of a new SkinGun™ patent by the United States Patent and Trademark Office.
Roseland, NJ – July 22, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com) today provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient.
Roseland, NJ – June 7st, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com) today announced that it is initiating a clinical trial at four burn centers in the United States. This follows the Company’s recent Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA).
Roseland, NJ – June 1st, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com) today announced that it intends to vigorously defend itself and its stockholders against allegations made by the U.S. Securities and Exchange Commission (“SEC”) in a civil complaint filed on May 28, 2021 regarding legacy events (the “Complaint”) from over 3 years ago.
Roseland, NJ – May 6th, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that its IDE application has been granted full approval by the FDA, enabling RenovaCare to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds.
Roseland, NJ – March 30th, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of organs and tissues, announced the new appointment of Dr. Kaiyo Nedd as Interim President & CEO, Harmel S. Rayat to serve as Chairman of the Board.
Roseland, NJ – February 25th, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at the 2021 H.C. Wainwright Global Life Sciences Conference, scheduled for March 9 – 10.